A phase III randomised open-label study of extended adjuvant therapy with camizestrant vs standard endocrine therapy (ET) in patients with ER+/HER2-early breast cancer (BC) and an intermediate or high risk of recurrence (CAMBRIA-1)

被引：1
|
作者：
Hamilton, E. [1 ]
Loibl, S. [2 ]
Niikura, N. [3 ]
Rastogi, P. [4 ]
Saini, K. S. [5 ]
Gioni, I. [6 ]
Klinowska, T. [6 ]
Mayer, I. [7 ]
Stuart, M. [6 ]
Syta, E. [8 ]
Walding, A. [6 ]
Bachelot, T. [9 ]
机构：
[1] Sarah Cannon Res Inst Tennessee Oncol, Med Oncol Dept, Nashville, TN USA
[2] German Breast Grp GBG Forschungs GmbH, Med & Res Dept, Neu Isenburg, Germany
[3] Tokai Univ, Sch Med, Breast Oncol Dept, Isehara, Kanagawa, Japan
[4] Univ Pittsburgh, Oncol Dept, Pittsburgh, PA USA
[5] Fortrea Inc, Global Clin Dev, Durham, NC USA
[6] AstraZeneca, Late Dev Oncol R&D, Cambridge, England
[7] AstraZeneca, Late Dev Oncol R&D, Gaithersburg, MD USA
[8] AstraZeneca Canada Inc, Late Dev Oncol, Toronto, ON, Canada
[9] Ctr Leon Berard, Med Oncol Dept, Lyon, France
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.3100
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
354TiP
引用
收藏
页码：S323 / S324
页数：2
相关论文
共 50 条
  • [31] Phase III open-label, multicenter, randomized trial of adjuvant palbociclib in combination with endocrine therapy versus endocrine therapy alone for patients with hormone receptor-positive/HER2-negative resected isolated locoregional recurrence of breast cancer - The POLAR Trial
    Munzone, Elisabetta
    Aebi, Stefan
    Janez, Noelia Martinez
    Guth, Uwe
    Bellet, Meritxell
    Pistilli, Barbara
    Balic, Marija
    Roschitzki-Voser, Heidi
    Regan, Meredith M.
    CANCER RESEARCH, 2021, 81 (04)
  • [32] OPERA-01: A randomized, open-label, phase 3 study of palazestrant (OP-1250) vs standard-of-care for ER+, HER2-advanced or metastatic breast cancer patients after endocrine therapy and CDK4/6 inhibitors
    Pistilli, Barbara
    Bellet, Meritxell
    Del Mastro, Lucia
    McArthur, Heather L.
    Meisel, Jane Lowe
    Schmid, Peter
    Sohn, Joohyuk
    De Kermadec, Elisabeth
    Wei, Rachel
    Chan, Arlene
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [33] KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab versus placebo in combination with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk early-stage ER+/HER2-breast cancer
    Cardoso, F.
    Bardia, A.
    Andre, F.
    Cescon, D. W.
    McArthur, H.
    Telli, M.
    Loi, S.
    Cortes, J.
    Schmid, P.
    Harbeck, N.
    Denkert, C.
    Jackisch, C.
    Jia, L.
    Tryfonidis, K.
    Karantza, V.
    CANCER RESEARCH, 2019, 79 (04)
  • [34] Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial
    Toi, Masakazu
    Imoto, Shigeru
    Ishida, Takanori
    Ito, Yoshinori
    Iwata, Hiroji
    Masuda, Norikazu
    Mukai, Hirofumi
    Saji, Shigehira
    Shimizu, Akira
    Ikeda, Takafumi
    Haga, Hironori
    Saeki, Toshiaki
    Aogi, Kenjiro
    Sugie, Tomoharu
    Ueno, Takayuki
    Kinoshita, Takayuki
    Kai, Yuichiro
    Kitada, Masahiro
    Sato, Yasuyuki
    Jimbo, Kenjiro
    Sato, Nobuaki
    Ishiguro, Hiroshi
    Takada, Masahiro
    Ohashi, Yasuo
    Ohno, Shinji
    LANCET ONCOLOGY, 2021, 22 (01): : 74 - 84
  • [35] HYPofractionated Adjuvant RadioTherapy in 1 versus 2 weeks in high-risk patients with breast cancer (HYPART): a non-inferiority, open-label, phase III randomised trial
    Yadav, Budhi Singh
    Dahiya, Divya
    Kannan, P.
    Goyal, Shikha
    Laroiya, Ishita
    Irrinki, Santhosh
    Singh, Ngangom Robert
    Sharma, Reena
    TRIALS, 2024, 25 (01)
  • [36] HYPofractionated Adjuvant RadioTherapy in 1 versus 2 weeks in high-risk patients with breast cancer (HYPART): a non-inferiority, open-label, phase III randomised trial
    Budhi Singh Yadav
    Divya Dahiya
    P. Kannan
    Shikha Goyal
    Ishita Laroiya
    Santhosh Irrinki
    Ngangom Robert Singh
    Reena Sharma
    Trials, 25
  • [37] OPERA-01: A randomized, open-label, phase 3, study of palazestrant (OP-1250) vs standard-of- care treatment for ER+, HER2-advanced or metastatic breast cancer after endocrine and CDK4/6 inhibitor therapy
    Chan, Arlene
    Meisel, Jane
    Jhaveri, Komal
    Sohn, Joo Hyuk
    Bellet-Ezquerra, Meritxell
    Schroeder, Jason
    Shilkrut, Mark
    Pistilli, Barbara
    CANCER RESEARCH, 2024, 84 (09)
  • [38] A randomized, open-label CECOG phase II study of dose-dense FEC 75 vs FEC 90 as adjuvant therapy in early breast cancer patients
    Kahan, S.
    Spanik, S.
    Wagnerova, M.
    Skacel, T.
    Planko, B.
    Fitzthum, E.
    Lindner, E.
    Soldatenkova, V.
    Zielinski, C. C.
    Brodowicz, T.
    EJC SUPPLEMENTS, 2007, 5 (04): : 211 - 212
  • [39] KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) plus chemotherapy (chemo), followed by adjuvant pembro or pbo plus endocrine therapy (ET) for early-stage high-risk ER+/HER2e breast cancer
    Cardoso, F.
    McArthur, H. L.
    Schmid, P.
    Cortes, J.
    Harbeck, N.
    Telli, M. L.
    Cescon, D. W.
    O'Shaughnessy, J.
    Fasching, P.
    Shao, Z.
    Loirat, D.
    Park, Y. H.
    Fernandez, M. E. Gonzalez
    Liu, Z.
    Yasojima, H.
    Ding, Y.
    Jia, L.
    Karantza, V. V.
    Tryfonidis, K. E.
    Bardia, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S1260 - S1261
  • [40] First prospective multicenter Italian study on the impact of the 21-gene recurrence score (RS) in adjuvant clinical decisions for ER1/HER2-early breast cancer (BC) patients
    Dieci, M. V.
    Guarneri, V.
    Giarratano, T.
    Mion, M.
    Tortora, G.
    Morandi, P.
    Gori, S.
    Merlini, L.
    Oliani, C.
    Pasini, F.
    Bonciarelli, G.
    Griguolo, G.
    Orvieto, E.
    Del Bianco, P.
    De Salvo, G. L.
    Conte, P.
    ANNALS OF ONCOLOGY, 2017, 28
12345